Diagnosys

Executive Summary

Diagnosys is a privately held diagnostics company headquartered in Cambridge, MA, specializing in visual function test systems for both preclinical and clinical applications. Founded in 2014, the company offers a complete suite of solutions including electroretinography (ERG), visual electrophysiology, psychophysical tests, objective acuity measurement, and pupillometry. Their flagship preclinical system, Celeris®, revolutionizes rodent testing with dual-function stimulator-electrodes, while their clinical portfolio provides comprehensive visual function assessment. With a focus on ophthalmic and neuroscience research, Diagnosys serves pharmaceutical companies, academic institutions, and clinical research organizations. The company has not disclosed total funding or valuation but remains a key player in the vision diagnostics space. Looking ahead, Diagnosys is well-positioned to capitalize on the growing demand for non-invasive, objective visual function tests. The company's clinical product line, which includes electrophysiology and psychophysical tools, is expected to drive revenue growth pending regulatory clearances. Key near-term catalysts include potential FDA 510(k) clearance for a new clinical diagnostic device, which would expand their market reach. Additionally, partnerships with pharmaceutical companies for preclinical safety testing of ocular therapeutics could accelerate adoption. A successful Series A funding round would provide capital for commercial scale-up and sales expansion. With a strong product portfolio and clear market need, Diagnosys is poised for growth in the ophthalmic diagnostics market.

Upcoming Catalysts (preview)

• Q1 2027FDA 510(k) clearance for new clinical diagnostic device70% success
• Q3 2026Strategic partnership with major ophthalmic pharmaceutical company for preclinical testing services60% success
• Q4 2026Series A funding round to commercialize clinical products80% success